Want to see PLX full AI Analyst Report?
PLX Stock Chart & Stats
$2.32
-$0.05(-2.01%)
At close: 4:00 PM EST
$2.32
-$0.05(-2.01%)
Day’s Range― - ―
52-Week Range$1.36 - $3.19
Previous CloseN/A
Volume368.29K
Average Volume (3M)627.79K
Market Cap
$190.95M
Enterprise Value$129.52M
Total Cash (Recent Filing)$51.79M
Total Debt (Recent Filing)$8.48M
Price to Earnings (P/E)12.5
Beta0.72
Next Earnings
Aug 17, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.19
Shares Outstanding80,571,640
10 Day Avg. Volume664,553
30 Day Avg. Volume627,794
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.93
Price to Sales (P/S)2.68
P/FCF Ratio-10.37
Enterprise Value/Market Cap0.68
Enterprise Value/Revenue1.70
Enterprise Value/Gross Profit2.42
Enterprise Value/Ebitda5.80
Forecast
1Y Price Target
$12.00Price Target Upside417.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.2
Revenue Forecast (FY)$78.30M
Bulls Say, Bears Say
Bulls Say
ProCellEx Platform & ManufacturingProtalix’s proprietary plant cell–based ProCellEx platform and in-house manufacturing that already supports marketed products create a durable competitive advantage. Owning production enables supply control, lower incremental costs for follow-on biologics, and makes the company an attractive partner for licensing and profit-share deals.
Strong Liquidity And Low LeverageA $25M milestone boosted cash to $51M and the company reports no debt or warrants, materially improving financial flexibility. This liquidity supports continued clinical programs, reimbursement rollouts, and commercialization investments without immediate financing, reducing near-term dilution and execution risk.
Improving Margins And Revenue GrowthRecent TTM performance shows a meaningful step-up: strong revenue growth and materially expanded gross and net margins. If sustainable, higher margins reflect operational leverage from product sales and lower cost of goods, improving free cash flow generation capacity and enabling reinvestment into R&D and commercialization.
Bears Say
Lumpy Cash Flow HistoryHistorical volatility in operating and free cash flow highlights dependence on episodic events (e.g., milestones) and timing of partner purchases. This lumpiness reduces visibility on the company’s ability to consistently fund programs and operations without recurring external payments or capital raises.
Partner / Milestone Concentration RiskA meaningful portion of revenue and near-term profitability is tied to partner payments (milestones, profit shares, royalties) and a small set of products. That concentration creates structural risk: partner demand, contract terms, or milestone timing can swing revenue materially and compress predictability over the medium term.
Commercial And Clinical Execution UncertaintyProduct sales decline and reliance on partner-led reimbursement rollouts create execution risk for commercial uptake. Separately, PRX-115 enrollment and timing remain uncertain. Execution delays or weaker-than-expected adoption would pressure revenue sustainability and extend the timeline to realize pipeline value.
Protalix News
PLX FAQ
What was Protalix Biotherapeutics’s price range in the past 12 months?
Protalix Biotherapeutics lowest stock price was $1.36 and its highest was $3.19 in the past 12 months.
What is Protalix Biotherapeutics’s market cap?
Protalix Biotherapeutics’s market cap is $190.95M.
When is Protalix Biotherapeutics’s upcoming earnings report date?
Protalix Biotherapeutics’s upcoming earnings report date is Aug 17, 2026 which is in 37 days.
How were Protalix Biotherapeutics’s earnings last quarter?
Protalix Biotherapeutics released its earnings results on May 13, 2026. The company reported $0.22 earnings per share for the quarter, beating the consensus estimate of -$0.01 by $0.23.
Is Protalix Biotherapeutics overvalued?
According to Wall Street analysts Protalix Biotherapeutics’s price is currently Undervalued.
Does Protalix Biotherapeutics pay dividends?
Protalix Biotherapeutics does not currently pay dividends.
What is Protalix Biotherapeutics’s EPS estimate?
Protalix Biotherapeutics’s EPS estimate is -0.01.
How many shares outstanding does Protalix Biotherapeutics have?
Protalix Biotherapeutics has 80,571,640 shares outstanding.
What happened to Protalix Biotherapeutics’s price movement after its last earnings report?
Protalix Biotherapeutics reported an EPS of $0.22 in its last earnings report, beating expectations of -$0.01. Following the earnings report the stock price went up 1.047%.
Which hedge fund is a major shareholder of Protalix Biotherapeutics?
Currently, no hedge funds are holding shares in PLX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Protalix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (417.24% Upside)
$12.00 (417.24% Upside)
Blogger Sentiment
Neutral
PLX Sentiment 50%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 6.8%
Last 30 Days ▼ 6.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
64.86%
12-Months-Change
Fundamentals
Return on Equity
28.10%
Trailing 12-Months
Asset Growth
38.49%
Trailing 12-Months
Company Description
Protalix Biotherapeutics
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
PLX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive financial and operational picture driven by a $25 million milestone that produced Q1 profitability and strengthened the balance sheet to $51 million in cash. Management reaffirmed 2026 guidance and highlighted commercial and regulatory progress for Elfabrio and continued advancement of the PRX-115 program. Offsetting risks include a notable decline in product sales quarter-over-quarter (-26% in selling goods), increased R&D spend (+54%), and timing/visibility uncertainties tied to Chiesi reimbursement rollouts and trial enrollment pace. Overall, the positives (milestone, cash position, profitability, reaffirmed guidance, and clinical progress) materially outweigh the near-term revenue timing and expense increases.View all PLX earnings summariesPLX Stock 12 Month Forecast
Average Price Target
$12.00
▲(417.24% Upside)
Technical Analysis
Coherus Biosciences
―
SELLAS Life Sciences Group
―
Protara Therapeutics
―
Forte Biosciences
―
Innate Pharma
―
Ownership Overview
3.87% Insiders
2.82% Mutual Funds
6.20% Other Institutional Investors
82.13% Public Companies and
Individual Investors